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INTRODUCTI ˙ON: This study aimed to investigate a number of demographic characteristics in males with osteoporosis
(OP) treated with bisphosphonate and determine whether any of these measures could act as an effective indicator
of medication persistence and compliance.
MATERIAL AND METHOD: Among the patients with OP who applied to our clinic and were prescribed weekly oral
bisphosphonate treatment, 89 patients over 50 years of age were included in this study. The demographic
characteristics of these patients were evaluated. The number of medications used by the patients over the past 1
and 3 years were counted, and the persistence and compliance with bisphosphonate treatment was estimated. The
patients were divided into two groups: fully compliant and noncompliant subjects. The two groups of patients were
compared separately for 1 and 3 years while considering their demographic characteristics.
RESULTS: The mean age of the 89 patients included in the study was 62.43¡9.41 years. Comparisons among the
studied demographic characteristics during the 1-year period of medication use indicated that the educational
status of the fully compliant patients was higher. During the 3-year period of medication use, educational status
was the only demographic characteristic that was determined to be significantly lower in the noncompliant patients
than in the fully compliant group.
CONCLUSION: Although deficiencies in medication persistence and compliance during osteoporosis treatment can
lead to serious health and social problems in both genders, the causes of these deficiencies have not been
thoroughly clarified. We suggest that the educational status of the patient may contribute to these deficiencies.
KEYWORDS: Osteoporosis; Bisphosphonates; Medication adherence; Medication persistence; Treatment
effectivenes.
Cevikol A, Umay E, Polat S, Ecerkale O, Cakci A. The relationship between bisphosphonate use and demographic characteristics of male osteoporosis
patients. Clinics. 2011;66(4):579-582.
Received for publication on October 3, 2010; First review completed on December 6, 2010; Accepted for publication on January 4, 2011
E-mail: ebruumay@gmail.com
Tel.: 90 3125962000
INTRODUCTION
Osteoporosis (OP) is a structural insufficiency of the bones
that is characterizedby low bone mass andthe impairment of
themicro-architecturalstructureofthebonytissue,leading to
increased bone fragility.
1,2 Because the increase in bone
fragility also increases morbidity and mortality, an accurate
early diagnosis and the initiation of an effective mode of
treatment are the basic aims of OP treatment.
3
Bisphosphonates are commonly used to treat and prevent
OP because of their low number of side effects and their
ability to inhibit bone resorption.
4 They are stable pyropho-
sphate analogs that decrease bone destruction by binding to
hydroxyapatite crystals in the bone.
5 It has been demon-
strated in the literature that these medications decrease the
formation of new fractures and increase the bone mineral
density (BMD).
6,7
Despite the reported effectiveness of bisphosphonates for
the treatment of OP, studies have shown that regular use and
medication compliance are much lower than expected.
8,9
Noncompliance reduces the effectiveness of medication
treatment, increases the risk of fractures and hospitalization,
and creates a serious socioeconomic burden.
10 Although the
resultsarecontroversial,possiblefactorsaffectingmedication
compliance have been reviewed in the literature and include
individualdemographiccharacteristicssuchasthecontinuity
of the medication treatment, patient gender, educational
status, diseases accompanying OP, additional medications
being taken, timing of medication administration (daily or
weekly) and the presence of side effects.
11-13
The aim of this study was to investigate a number of
demographic characteristics to determine whether any was
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compliance in males with OP who were being treated with
bisphosphonate.
MATERIALS AND METHODS
Among the patients who applied to our clinic with OP
and who were prescribed weekly oral bisphosphonate
treatment, a total of 89 patients over 50 years of age were
included in this study. OP treatment was given to patients
who had a vertebra/femur BMD of22.5 or below, along
with risk factors and/or the presence of clinic symptoms
such as extreme kyphosis, back pain, height loss, and so
forth. The files of these patients were examined retro-
spectively. Patients under 50 years of age with secondary
OP or those who first presented with OP during the
previous 3 years were not included in the study.
The demographic characteristics of the patients included
the following details: age; educational level; smoking habits;
alcohol consumption; a history of previous fractures; the
presence of gastrointestinal system diseases (GIS), such as
gastritis or peptic ulcers; the presence of accompanying
diseases, such as hypertension or diabetes mellitus; and the
presence of additional prescribed medications other than
those for OP.
In the evaluation of the demographic characteristics, age
is indicated by the year of birth and education level is
indicated as one of the following: illiterate, literate,
elementary school, junior high school, high school, higher
education vocational school or university. Smoking habits,
alcohol consumption, history of previous fractures, the
presence of GIS disorders, the presence of comorbidities and
the use of additional medications are indicated by the
numbers of patients.
At an interval of every three months, the patients were
called to the hospital to detect medication levels and were
followed for three years.
The amounts of medications used by the patients for 1
and 3 years were measured and the persistence and
compliance with bisphosphonate treatment were estimated.
The persistence of medication use was estimated by
calculating the number of medications taken relative to the
number of medications prescribed for 1 and 3 years.
Medication compliance was defined as the full administra-
tion of medications without skipping any doses and without
reducing or increasing the dosage. According to this
definition, ‘‘full medication compliance’’ was considered
as a persistence rating of the medication for 1 and
3 years that was equivalent to 1.
The eighty-nine patients were divided into two groups:
fully compliant and noncompliant patients. Fully compliant
and noncompliant patients were compared separately after
1 year (n=44 and n=45, respectively) and after 3 years
(n=16 and n=73, respectively) according to their demo-
graphic characteristics.
Data analysis was performed using the Statistical Package
for the Social Sciences (SPSS) for Windows 11.0. The results
are presented as the mean ¡ standard deviation and the
number of observations (%) using a chi-square test.
Significant differences between the rates of persistence and
medication compliance, as well as differences in the
demographic characteristics of fully compliant and non-
compliant patients, were analyzed with a Pearson chi-
square correlation test. Logistic regression analysis was
performed for the correlations that were found to be
significant. Results were considered to be significant for
values of p,0.05.
RESULTS
The mean age of the 89 patients included in the study was
62.43¡9.41 years and the majority of these patients had
completed elementary school. The demographic character-
istics of these patients are given in Table 1.
More than 50% of the patients were smokers and nearly
50% presented another disease in addition to OP.
All of the patients were receiving alendronate treatment
administered weekly and the number of medication tablets
prescribed at 1 year was 52 and the number at 3 years was
156 tablets. One patient (1.1%) had not used the medication
at all at the 1-year and 3-year follow-ups. The number of
medications used during the treatment period and the
distribution of data for full medication compliance are given
in Table 2.
A total of 44 patients were in full compliance during the 1-
year follow-up, whereas fewer remained in this group at the
3-year follow-up (n=16, 17.9%).
The rate of persistence at the 1-year follow-up was
0.77¡0.23 0.57 (0.0-1.0) and the persistence rate at the 3-
year follow-up was 0.38¡0.30 0.19 (0.0-1.0). Upon compar-
ing the medication persistence rates, it was observed that
the rate of persistence decreased with long-term use
(r=20.660, p=0.001).
Upon comparing the full compliance rates for the 1- and
3-year periods (49.4% and 17.9%, respectively), it was
observed that compliance decreased with long-term use
(r=20.491, p=0.005). A comparison of the demographic
characteristics of patients at the 1- and 3-year follow-up
periods according to rates of compliance and noncompli-
ance is indicated in Table 3.
Comparison of the studied demographic characteristics
during the 1-year period of medication use demonstrated
that educational status was higher in the fully compliant
patients. In contrast, smoking habits, alcohol consumption,
fracture history and the presence of additional diseases and
Table 1 - Distribution of the demographic characteristics
of the patients.
Demographic characteristics Avg ¡ SS, n(%)
n=89
Age (years) 62.43¡9.41
Educational status
Illiterate 1 (1.1)
Literate 1 (1.1)
Elementary school 47 (52.9)
Junior high school 11 (12.4)
High school 17 (19.1)
Higher education vocational school 2 (2.3)
University 9 (10.1)
Number of smokers 48 (53.9)
Number patients consuming alcohol 15 (16.9)
History of previous fracture 20 (22.5)
Presence of GIS disorders 17 (19.1)
Presence of comorbidities 43 (48.3)
Use of additional medications 25 (28.1)
Avg ¡ SS: average¡ standard deviatione.
GIS: Gastrointestinal system.
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relative to the noncompliant patients. Although the
presence of diseases accompanying OP and the use of
additional medications were observed less frequently in the
fully compliant patients, these differences were not sig-
nificant (p.0.05). During the 3-year period of medication
use, only educational status was significantly lower in the
noncompliant patients when compared with the fully
compliant group (p,0.05). According to the regression
analysis, educational status effectively influenced the long-
term compliance rate among males treated for OP (odds
ratio=0.34, p=0.001).
DISCUSSION
Until recently, OP has been discussed as a ‘‘woman’s
disease’’ in the literature and studies frequently involve
only females. In 2007, OP was reported as an important
health issue in males as well and was described as a serious
socioeconomic burden.
14 Although OP is recognized as
occurring less frequently in males, the morbidity and
mortality rates in males are higher than in females.
15
Although this difference is attributed to the more advanced
age of onset in males, the cause has not been fully
elucidated. In a study by Kamatari et al.,
16 which included
1274 patients with OP, it was reported that medication
compliance in males was lower than in females; however,
the cause of this noncompliance was not investigated in
their study.
In our study, we aimed to determine whether any of the
investigated demographic characteristics were effective
indicators of medication persistence and compliance in
males with OP. On the basis of the results of this study, it
was determined that educational status was associated with
medication compliance in the long term and with medica-
tion persistence. In addition, medication compliance dimin-
ished as the treatment period progressed. Medication
compliance was not affected by age, smoking habits, alcohol
consumption, fracture history, the presence of gastrointest-
inal diseases, accompanying diseases and additional med-
ications.
There is only one study in the literature investigating the
factors affecting medication compliance among males with
OP. Hansen et al.
17 studied 198 males with OP and
examined age, race, body weight, smoking and alcohol
habits, fracture history, additional medications and the
presence of side effects related to the medication. They
reported that compliance was better in the younger patients
(mean age of 69) and in the non-smokers after 1 year of
medication use. After 2 years of medication use, compliance
was better in non-smokers and in those who experienced
fewer side effects related to the medication. In that study,
full compliance with the medication was reported to be 59%
during the first year and 54% at the end of the second year.
Our study differs from that study because the mean age of
our patients was lower and because we also evaluated the
presence of gastrointestinal disease, compliance after a 3-
year treatment period, educational status and the presence
of accompanying diseases. Although Hansen’s study
17 is
not directly comparable to ours, when the 1-year results
were compared with those of our study, factors such as
alcohol consumption, fracture history and additional med-
ications did not affect compliance during a 1-year treatment
period; although, medication compliance did decrease by
50% over the 1-year treatment period.
In our study, we determined that smoking habits did not
affect compliance with treatment. Although the smoking
rate was 53.9% in our study, the same rate was 33% in the
study by Hansen et al.
17 This difference may be due to the
differences in the study groups and health policies of the
respective countries. The study by Hansen et al.
17 was
performed among United States veterans and we believe
that this difference may reflect the lower rates of smokers in
the U.S. as compared with Turkey or the higher educational
status of those individuals compared with the participants
in our study.
In addition, despite the results of Hansen et al.
17 that
indicate that the presence of side effects from the medication
are effective indicators, the results of these two studies
cannot be compared because the current study aimed only
to evaluate whether or not certain demographic character-
istics of patients were associated with medication persis-
tence and compliance. However, we did not evaluate
medication side effects in the current study.
To the best of our knowledge, there are no other studies
on medication persistence and medication compliance in
males with OP. However, according to studies in the
literature performed among postmenopausal females with
OP, medication persistence and medication compliance
were better in females with a higher education, which is
Table 2 - Distribution of data related to the treatment of
patients with medications.
Avg ¡ SS, n(%)
n=89
Number of medications to be used in 1 year 52.00¡00.00
Number of medications to be used in 3 years 156.00¡00.00
Number of medications used in 1 year 40.40¡11.83
Number of medications used in 3 years 60.25¡47.30
Number of patients using medications in 1 year 88 (98.9)
Number of patients using medications in 3 years 88 (98.9)
Full medication compliance in 1 year 44 (49.4)
Full medication compliance in 3 years 16 (17.9)
Avg ¡ SD: average ¡ standard deviation.
Table 3 - Comparison of demographic characteristics
during the 1- and 3-year follow-ups, according to the
rates of compliance and noncompliance.
in 1 year in 3 years
Rpr p
Age 0.071 0.624 1.00 0.467
Educational status -0.018 0.101 -0.121 0.001
Smoking -0.075 0.452 -0.088 0.377
Alcohol consumption -1.924 0.054 -0.097 0.923
Presence
of fractures
0.006 0.952 0.101 0.458
Presence of
GIS disorders
-0.023 0.827 0.019 0.610
Presence of additional
comorbidities
-0.012 0.913 0.045 0.671
Presence of additional
medications
-0.018 0.865 0.078 0.462
GIS: Gastrointestinal system. r: Correlation coefficient.
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18 We think that this
finding may be attributed to the fact that such patients
better comprehend the severity of OP, the necessity of an
effective treatment and acknowledge the optimal means of
using the medication.
CONCLUSION
Although deficiencies in medication persistence and
medication compliance during OP treatment can lead to
serious health and social problemsin both genders, the causes
of these deficiencies are not fully understood. Although the
side effects of these medications are frequently reported as
effective indicators of persistence and compliance, clinicians
should note that factors specific to each patient can also play a
role, particularly with respect to long-term use. Education
may be the factor that most affects the outcome of long-term
treatments. Even if the initiation of a medication does not
seem very important, compliance during treatment and
follow-up is extremely important. Furthermore, to under-
stand the importance of education level on medication
compliance, large-scale and comprehensive studies evaluat-
ing the effects of demographic characteristics on medication
compliance are required.
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